Hypertension, Essential
12
2
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.3%
1 terminated out of 12 trials
88.9%
+2.4% vs benchmark
25%
3 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant
A Study to Evaluate the Efficacy and Safety of AD-209
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension
Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension